Sato Shintaro, Kurachi Moegi, Ohta Hiroki, Nakamura Tomohiko, Oba Tomohiro, Kawabe Rie, Yamakawa Hideaki, Amano Masako, Matsushima Hidekazu
Department of Respiratory Medicine, Saitama Red Cross Hospital, Saitama, Japan.
Department of Hematology, Saitama Red Cross Hospital, Saitama, Japan.
Respir Med Case Rep. 2021;34:101563. doi: 10.1016/j.rmcr.2021.101563. Epub 2021 Dec 2.
A 72-year-old Japanese man was admitted to our hospital for treatment of severe COVID-19 pneumonia and was started on favipiravir, heparin calcium, and methylprednisolone pulse therapy. He recovered from respiratory failure about one month later. However, he soon developed purpura in his lower limbs and thrombocytopenia, and immune thrombocytopenia was subsequently diagnosed. Although immune thrombocytopenia is one of the early complications of COVID-19, the use of corticosteroids for COVID-19 is thought to be a factor in the late onset of immune thrombocytopenia. In cases of severe COVID-19 for which corticosteroids were used for treatment, autoimmune diseases such as immune thrombocytopenia may manifest themselves late in the disease course.
一名72岁的日本男性因重症新型冠状病毒肺炎入院治疗，开始使用法匹拉韦、肝素钙和甲泼尼龙冲击疗法。大约一个月后，他从呼吸衰竭中康复。然而，他很快出现下肢紫癜和血小板减少，随后被诊断为免疫性血小板减少症。虽然免疫性血小板减少症是新型冠状病毒肺炎的早期并发症之一，但使用皮质类固醇治疗新型冠状病毒肺炎被认为是免疫性血小板减少症延迟发生的一个因素。在使用皮质类固醇治疗的重症新型冠状病毒肺炎病例中，免疫性血小板减少症等自身免疫性疾病可能在病程后期出现。
